Piper Sandler analyst Jessica Tassan raised the firm’s price target on Health Catalyst (HCAT) to $12 from $11 and keeps an Overweight rating on the shares. The firm is updating its model to reflect revised 2024 guidance and Health Catalyst’s expectation for approximately 50% adjusted EBITDA growth year-over-year in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target raised to $12 from $11 at Piper Sandler
- Health Catalyst price target raised to $9 from $7 at Stephens
- Health Catalyst price target raised to $10.50 from $9 at Citi
- Health Catalyst Reports Q3 Revenue Growth Amid Reduced Losses
- Health Catalyst announces partnership with CyncHealth